- Nurix Therapeutics (NASDAQ:NRIX) announces the pricing of its upsized underwritten public offering of 10.17 million shares of its common stock at $15.00 per share, with an expected gross proceeds of $175.0 million.
- The offering was increased from previously announced $125 million to $175 million.
- In addition, Nurix (NRIX) is offering pre-funded warrants to investors to purchase up to 1,500,100 shares of common stock for $14.999 per warrant, less the exercise price.
- In connection with the offering, the company has granted the underwriters a 30-day option to purchase up to an additional 1.75 million shares.
- The offering is expected to close on April 16, 2024.
- All the securities are being offered by Nurix.
- Shares were down 6.33% in pre-market trade on Friday.
